PANITUMUMAB and RASH

Overview

RASH is the #1 most commonly reported adverse reaction for PANITUMUMAB, manufactured by Amgen, Inc. There are 1,722 FDA adverse event reports linking PANITUMUMAB to RASH. This represents approximately 5.4% of all 31,648 adverse event reports for this drug.

Patients taking PANITUMUMAB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

RASH is moderately reported among PANITUMUMAB users, representing a notable but not dominant share of adverse events.

Other Side Effects of PANITUMUMAB

In addition to rash, the following adverse reactions have been reported for PANITUMUMAB:

• DIARRHOEA — 1,526 reports
• DERMATITIS ACNEIFORM — 1,005 reports
• DEATH — 908 reports
• NEUTROPENIA — 886 reports
• SKIN TOXICITY — 850 reports
• HYPOMAGNESAEMIA — 793 reports
• NAUSEA — 780 reports
• DISEASE PROGRESSION — 712 reports
• NEUROPATHY PERIPHERAL — 688 reports
• COLORECTAL CANCER METASTATIC — 625 reports

Other Drugs Associated with RASH

The following drugs have also been linked to rash in FDA adverse event reports:

Does PANITUMUMAB cause RASH?

RASH has been reported as an adverse event in 1,722 FDA reports for PANITUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is RASH with PANITUMUMAB?

RASH accounts for approximately 5.4% of all adverse event reports for PANITUMUMAB, making it one of the most commonly reported side effect.

What should I do if I experience RASH while taking PANITUMUMAB?

If you experience rash while taking PANITUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages